Gameto has announced a historic milestone in reproductive medicine with the world’s first live birth achieved through its innovative Fertilo technology. The delivery, which took place at Santa Isabel Clinic in Lima, Peru, marks a significant leap forward in fertility treatment, offering hope for a more efficient and less invasive approach to assisted reproduction.
Traditional in-vitro fertilization (IVF) typically involves a 10–14 day regimen of high-dose hormone injections to mature eggs, a process that can be physically demanding and emotionally taxing. In contrast, Fertilo uses engineered ovarian support cells (OSCs) to replicate the natural egg maturation process outside the body, reducing the reliance on hormone injections by 80% and cutting treatment cycles to just three days.
“We are thrilled to celebrate the first live birth conceived using Fertilo,” said Dr. Dina Radenkovic, CEO and co-founder of Gameto. “This achievement overcomes many of the challenges faced with conventional IVF, such as long treatment durations, significant side effects, and the emotional strain on families. Fertilo presents a faster, safer, and more accessible fertility solution, marking a pivotal moment in reproductive health and showcasing the potential of iPSC technology in IVF.”
The breakthrough also represents the first-ever successful application of induced pluripotent stem cell (iPSC) technology in IVF, offering new hope for improving IVF outcomes and advancing women’s health. By enabling the maturation of eggs outside the body with minimal hormonal intervention, Fertilo reduces the risks associated with traditional IVF treatments, including ovarian hyperstimulation syndrome and other side effects from high hormone doses.
Dr. Luis Guzmán, PhD, leader of Pranor Labs & Science, which facilitated the Fertilo IVF cycle, hailed the development as a “historic milestone” for reproductive medicine. “The ability to mature eggs with minimal hormonal intervention significantly reduces risks and alleviates the side effects caused by conventional high-dose hormone treatments,” he said.
The mother of the breakthrough baby expressed her gratitude for the Fertilo method, which she said was a gentler, less invasive option compared to traditional IVF. “With fewer injections and a more reassuring egg retrieval process, Fertilo made this deeply personal journey easier, both physically and emotionally. I am incredibly thankful to the Pranor Clinic and Gameto for helping me achieve my dream of starting a family,” she shared.
By reducing the need for hormonal stimulation and maturing eggs outside the body, Gameto believes Fertilo enhances IVF outcomes while offering a more streamlined process that results in high-quality eggs with similar success rates to conventional IVF but in a fraction of the time. The technology’s potential to reduce complications makes it an appealing alternative for women using assisted reproductive technologies.
Gameto’s goal with Fertilo is to make IVF and egg freezing faster, safer, and more accessible by minimizing the hormonal burden traditionally associated with egg maturation. The company has already received regulatory approvals for Fertilo’s commercialization in Australia and several large markets in Latin America, with plans for further expansion.
This breakthrough in fertility treatment opens new doors for improving reproductive health and reshaping the future of IVF.
Related topics:
NJ Bill Seeks Fertility Preservation Coverage for Patients Facing Medical Risks
America’s Fertility Decline: A Demographic Puzzle with Economic Implications
